IDXX

IDXX

USD

IDEXX Laboratories Inc. Common Stock

$722.120+4.680 (0.652%)

السعر في الوقت الحقيقي

Healthcare
Diagnostics & Research
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$717.440

الأعلى

$726.500

الأدنى

$707.755

الحجم

0.58M

أساسيات الشركة

القيمة السوقية

57.8B

الصناعة

Diagnostics & Research

البلد

United States

إحصاءات التداول

متوسط الحجم

0.48M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $356.14الحالي $722.120الأعلى $735

تقرير تحليل الذكاء الاصطناعي

آخر تحديث: ٣ نوفمبر ٢٠٢٥
تم إنشاؤه بواسطة الذكاء الاصطناعيمصدر البيانات: Yahoo Finance, Bloomberg, SEC

IDEXX (IDXX) on the Launchpad? A Fresh Upgrade Could Fuel the Next Big Move

Generated: November 03, 2025, 10:05 AM EDT

The Headline That Changed Everything

The story for IDEXX Laboratories right now boils down to one powerful piece of news. On the last day of October, analysts at Stifel didn't just nudge their rating; they upgraded the stock from Hold to Buy. More importantly, they boosted their price target to a hefty $700. This isn't just noise. A move this decisive from a respected firm often forces the market to pay attention, acting as a strong catalyst that can shift investor sentiment almost overnight. The data shows this news is viewed as overwhelmingly positive, and it's the central force driving the current conversation around the stock.

A Volatile Past Sets a Tense Stage

Looking at the stock chart tells a story of explosive energy followed by a long period of consolidation. Back on August 4th, the stock absolutely rocketed from the $530s to over $680 in a single session on massive volume. That move set a new high-water mark for the year. Ever since that peak, the stock has been digesting the huge gain, trading mostly in a wide range between the low $620s and the mid $660s.

This recent history is critical. The stock has pulled back from its highs and is now hovering just above a support level around $628. After months of sideways action, the price is coiled. The arrival of a major analyst upgrade at this specific technical juncture is what makes the current situation so compelling. The stage is set for a potential breakout.

When the Machines Agree with Wall Street

The algorithmic forecast adds another layer of conviction to the bullish short-term picture. The AI model is not fighting the trend; it's leaning into it. It projects a string of positive days ahead:

  • Day 1: +3.13%
  • Day 2: +2.35%
  • Day 3: +4.40%

This isn't just a vague prediction. The system shows high confidence and projects a move toward a target price of $669.81. When a major analyst upgrade, a tense technical setup, and a confident AI forecast all point in the same direction, it creates a powerful argument for a near-term move higher. The data suggests the recent buying pressure is extremely strong, with trading volume surging well beyond its average.

The Bottom Line

The evidence points toward a short-term trading opportunity in IDEXX, driven by the powerful catalyst of the Stifel upgrade. While the company's fundamentals raise long-term questions--specifically its high valuation (P/E of 52.6) and debt levels--the immediate momentum appears to be strongly positive. This is a play on sentiment and technicals, not a classic value investment.

For traders aligned with a short-term horizon (1-2 weeks), the data suggests a specific strategy:

  • Potential Entry Zone: The analysis identifies a tight cluster of entry points between $629.95 and $632.23.
  • Profit Target: A disciplined exit could be considered around $641.13.
  • Risk Management: A stop-loss order near $565.70 is suggested to protect against a sharp reversal.

This setup is built on the idea that the recent positive news will provide enough fuel to break the stock out of its recent range.


Disclaimer: This report is for informational purposes only and is not intended as investment advice. The analysis is based exclusively on the structured data provided and does not constitute a recommendation to buy or sell any security. All investments involve risk, and you should conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.

أخبار ذات صلة

Analyst Upgrades

Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $805

Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories with a Overweight and raises the price target from $765 to $805.

عرض المزيد
Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $805
Analyst Upgrades

UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $750

UBS analyst Andrea Alfonso maintains IDEXX Laboratories with a Neutral and raises the price target from $710 to $750.

عرض المزيد
UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $750
Analyst Upgrades

JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $775

JP Morgan analyst Chris Schott maintains IDEXX Laboratories with a Overweight and raises the price target from $675 to $775.

عرض المزيد
JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $775
Analyst Upgrades

BTIG Maintains Buy on IDEXX Laboratories, Raises Price Target to $830

BTIG analyst Mark Massaro maintains IDEXX Laboratories with a Buy and raises the price target from $785 to $830.

عرض المزيد
BTIG Maintains Buy on IDEXX Laboratories, Raises Price Target to $830
Reuters

S&P 500, Nasdaq gain after Amazon-OpenAI deal; Kenvue soars after buyout

The S&P 500 and Nasdaq kicked off November on firmer ground on Monday, after a slew of AI deals boosted megacap companies Amazon and Nvidia, while Kenvue shares soared after Kimberly-Clark's buyout deal.

عرض المزيد
S&P 500, Nasdaq gain after Amazon-OpenAI deal; Kenvue soars after buyout
Analyst Upgrades

Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook

Idexx stock gains after Q3 earnings and revenue beat expectations, driven by strong CAG growth and raised 2025 earnings and sales guidance.

BusinessWire

IDEXX Laboratories Announces Third Quarter Results

Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong organic revenue growth was supported by IDEXX

تنبؤ الذكاء الاصطناعيBeta

توصية الذكاء الاصطناعي

صعودي

تم التحديث في: ٤ نوفمبر ٢٠٢٥، ٠٨:٢٢ م

هبوطيمحايدصعودي

69.1% الثقة

المخاطر والتداول

مستوى المخاطرة3/5
مخاطرة متوسطة
مناسب لـ
متحفظ
دليل التداول

نقطة الدخول

$634.04

جني الأرباح

$643.73

وقف الخسارة

$568.00

العوامل الرئيسية

يظهر مؤشر DMI اتجاهًا هبوطيًا (ADX:18.7، +DI:7.3، -DI:9.7)، مما يشير إلى الحذر
حجم التداول 14.9 ضعف المتوسط (4,744)، مما يشير إلى ضغط شراء قوي للغاية
مؤشر MACD -0.0464 فوق خط الإشارة -0.3913، مما يشير إلى تقاطع صعودي

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.